Equities Analysts Offer Predictions for Chemours Q2 Earnings

The Chemours Company (NYSE:CC - Free Report) - Investment analysts at Zacks Research dropped their Q2 2025 earnings per share estimates for Chemours in a research note issued to investors on Monday, May 19th. Zacks Research analyst R. Department now anticipates that the specialty chemicals company will earn $0.47 per share for the quarter, down from their previous forecast of $0.58. The consensus estimate for Chemours' current full-year earnings is $2.03 per share. Zacks Research also issued estimates for Chemours' Q3 2025 earnings at $0.52 EPS, Q4 2025 earnings at $0.34 EPS, FY2025 earnings at $1.46 EPS, Q1 2026 earnings at $0.38 EPS, Q2 2026 earnings at $0.67 EPS, FY2026 earnings at $2.24 EPS, Q1 2027 earnings at $0.53 EPS and FY2027 earnings at $2.57 EPS.

A number of other equities analysts have also weighed in on CC. Morgan Stanley decreased their target price on Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a research report on Monday, May 12th. Royal Bank of Canada decreased their price objective on shares of Chemours from $17.00 to $14.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. Truist Financial decreased their target price on shares of Chemours from $27.00 to $22.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Wall Street Zen lowered Chemours from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Finally, Mizuho set a $15.00 target price on Chemours in a report on Tuesday, April 15th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, Chemours has a consensus rating of "Hold" and a consensus price target of $17.56.

Chemours Stock Down 5.1%

NYSE CC traded down $0.56 during trading hours on Wednesday, reaching $10.30. 2,992,136 shares of the company's stock traded hands, compared to its average volume of 2,091,743. The firm has a 50-day simple moving average of $11.97 and a 200 day simple moving average of $15.95. The firm has a market cap of $1.54 billion, a PE ratio of 18.06 and a beta of 1.76. Chemours has a 52-week low of $9.33 and a 52-week high of $26.98. The company has a debt-to-equity ratio of 6.70, a current ratio of 1.68 and a quick ratio of 0.92.

Chemours (NYSE:CC - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by ($0.06). Chemours had a return on equity of 26.54% and a net margin of 1.51%. The firm had revenue of $1.37 billion for the quarter, compared to analysts' expectations of $1.36 billion. During the same quarter in the prior year, the company posted $0.32 earnings per share. The business's revenue for the quarter was up .4% on a year-over-year basis.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC acquired a new position in shares of Chemours in the 1st quarter worth approximately $27,000. UMB Bank n.a. grew its stake in shares of Chemours by 73.9% in the first quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock valued at $30,000 after buying an additional 948 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Chemours by 170.7% in the 1st quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock valued at $30,000 after buying an additional 1,444 shares during the period. SouthState Corp acquired a new position in Chemours during the 1st quarter worth about $34,000. Finally, Quadrant Capital Group LLC lifted its position in shares of Chemours by 100.4% during the fourth quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock worth $38,000 after purchasing an additional 1,119 shares in the last quarter. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Shane Hostetter bought 4,450 shares of the company's stock in a transaction on Monday, May 19th. The stock was bought at an average cost of $11.28 per share, for a total transaction of $50,196.00. Following the acquisition, the chief financial officer now directly owns 59,694 shares in the company, valued at $673,348.32. This represents a 8.06% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.47% of the stock is currently owned by company insiders.

Chemours Dividend Announcement

The company also recently announced a dividend, which will be paid on Monday, June 16th. Investors of record on Monday, May 19th will be paid a $0.0875 dividend. This represents a dividend yield of 3.17%. The ex-dividend date of this dividend is Friday, May 16th. Chemours's dividend payout ratio is currently 175.00%.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.